Aureka Raises $100M Series B for Biological World Model

Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Aureka Biotechnologies closed a $100 million Series B on August 10, 2026. The round came in tranches: Granite Asia funded the first one on its own, and a strategic investor led a later tranche with HighLight Capital participating and existing shareholders MPCi and NRL Capital following on.

That brings total funding for the Laguna Hills company to nearly $200 million since it was founded in 2023.

Aureka describes itself as an AI native TechBio company, and its ambition is to build what it calls a biological world model. In practice that means a generation of biological foundation models wrapped in closed loop infrastructure, pulling together AI models, agents, digital biology and experimental platforms so that predictions get tested and the results feed back into training.

Most of the money goes to research and large scale training of the next model generation, with performance targets on three core tasks: de novo molecular design, biological structure modeling and function prediction.

The bet across this part of biotechnology is that drug discovery can be redesigned end to end rather than accelerated in pieces. Aureka now has the capital to find out whether that holds.

Contract researchers, suppliers and service firms selling into drug developers can reach verified contacts at newly funded companies through B2B Lead Generation For BioTech.